Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

June 6, 2018
Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF, suggesting the potential as an antifibrotic, anti-inflammatory and pro-tissue repair mechanism.
Previous Video
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Conge...

No More Videos